BPO TV

In this instalment of Bell Direct’s From the helm series, Jessica Amir speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt.

Immutep has gained a lot of attention, as its trials in collaboration with big-names, Pfizer and Merck, has seen a remission in patients' tumours. Between capital raisings and partnerships, Immutep continues to deliver impressive results...
 
In this video Marc discusses:

• (0:40) IMM's progress: the year that was, and the year ahead
• (1:30) Promising results from an IMM study in collaboration with Pfizer and Merck
• (2:29) Its unique discovery in immunotherapy - which spells new opportunities
• (4:02) Key catalysts that could drive share price growth
• (6:00) Fund managers who bought into IMM recently - and how funds raised will be spent

Note: This interview was filmed on 18 August 2021.